Eli Lilly’s Foundayo captures one-third of new US oral weight-loss pill starts
Eli Lilly CEO Dave Ricks announced that Foundayo now accounts for one in three new oral weight-loss drug starts in the US, with market share growing weekly. The company broke ground on a $6.5 billion manufacturing facility in Houston, Texas, expected to be operational by 2030. Foundayo generated $98 million in second-quarter revenue since its April US launch. The drug competes with Novo Nordisk’s Wegovy pill, and Lilly held about 61% of the overall weight-loss and diabetes market in the second quarter.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both sides agree that Eli Lilly's Foundayo and the broader GLP-1 drug market reveal deep problems in how healthcare is delivered, whether in the US or China.
- Both acknowledge that the current system—whether driven by corporate profit or state control—leaves many patients without adequate access to affordable medicine.
- Both recognize that pharmaceutical sovereignty and domestic manufacturing are becoming key geopolitical priorities for major powers like the US and China.
Points of contention
- The Western Agent argues that the US system, though broken, allows for public debate, protest, and the possibility of reform, while China's system silences dissent and lacks accountability.
- The Eastern Agent counters that US transparency has not led to lower prices or universal coverage, while China's centralized procurement has cut drug costs by 50-90% and covers 1.4 billion people.
- The Western Agent claims that China's system rations access based on political loyalty and lacks patient agency, while the Eastern Agent insists that access is based on medical need and that rural coverage is real, if imperfect.
Blind spots
- Neither side fully addresses how patients in both systems navigate the gap between policy and real-world care, such as bureaucratic hurdles or insurance denials.
- The debate overlooks the role of global supply chains and how both US and Chinese drug manufacturing depend on each other for raw materials and active ingredients.
- Both agents focus on national systems but ignore the experiences of patients in low-income countries who have no access to these drugs at all.
WorldAttention’s read
This debate shows that both the US and Chinese healthcare systems have serious flaws, but they fail in different ways. The US system offers transparency and the right to protest, yet it leaves millions uninsured and unable to afford life-saving drugs. China's system delivers lower prices and near-universal coverage, but it does so without independent oversight or the ability for patients to challenge decisions. Neither side fully addresses the real-world struggles patients face every day, like navigating insurance red tape or waiting for understocked clinics. The core challenge remains the same everywhere: how to make effective medicines like Foundayo affordable and accessible to everyone, not just the wealthy or well-connected. Until both systems put patient welfare above profit or political control, the true winners will be neither the US nor China, but the people who continue to go without care.
Reporting timeline
Lilly CEO says Foundayo captures one-third of new US oral weight loss pill starts
Eli Lilly CEO Dave Ricks stated on Monday that the company's oral weight loss drug Foundayo now accounts for one in three new oral weight loss drug starts in the United States, with its market share growing weekly. In an exclusive interview with CNBC, Ricks expressed long-term confidence in Lilly's position in the pill segment and announced plans for Foundayo rollouts in additional countries later this year. The comments coincided with Lilly breaking ground on a $6.5 billion manufacturing facility in Houston, Texas, expected to be operational by 2030, which will produce Foundayo and chemical components for other treatments. Foundayo entered the US market in April and generated $98 million in second-quarter revenue. The start of Medicare obesity drug coverage in July is seen as a catalyst for further uptake. Lilly's oral drug competes with a pill from Novo Nordisk, and Lilly held about a 61% share of the overall weight loss and diabetes market in the second quarter. Foundayo launched in the UK in August, priced between £100 and £120 per month. Shares of Novo Nordisk dropped Monday after its long-term strategy failed to reassure investors about competition with Lilly.
Read sourceLilly CEO says Foundayo captures one in three new US oral weight loss pill starts
Eli Lilly CEO Dave Ricks stated on Monday that Foundayo, the company's oral weight loss pill, now accounts for one in three new oral weight loss drug starts in the United States, with its market share growing weekly. Ricks expressed long-term confidence in Lilly's position in the pill segment and announced planned rollouts in additional countries later this year. The comments coincided with Lilly breaking ground on a $6.5 billion manufacturing facility in Houston, Texas, expected to be operational by 2030, which will produce Foundayo and other drug components. Foundayo entered the US market in April and generated $98 million in second-quarter revenue. The start of Medicare obesity drug coverage in July is seen as a catalyst for further uptake. Lilly's oral drug competes with a pill from Novo Nordisk, and Lilly held about a 61% share of the overall weight loss and diabetes market in the second quarter. Foundayo launched in the UK in August, priced between £100 and £120 per month. Shares of Novo Nordisk fell on Monday after its long-term strategy failed to reassure investors about competition with Lilly.
Eli Lilly CEO: One-Third of New GLP-1 Oral Patients Take Foundayo; Production Ramped Up
Eli Lilly CEO Dave Ricks stated on Monday that one-third of new patients taking oral GLP-1 drugs are using the company's Foundayo, as the pharmaceutical giant works to catch up to rival Novo Nordisk in the market. Ricks expressed long-term confidence in Lilly's oral tablet market position, especially with plans to launch Foundayo in more international markets in the coming months. The comments came as Lilly broke ground on a $6.5 billion manufacturing facility in Houston, Texas, expected to begin operations by 2030. The plant will primarily produce Foundayo, which entered the U.S. market in April, along with active ingredients for other small-molecule drugs. Lilly has committed over $50 billion since 2020 to expand its manufacturing network, including $27 billion in new investments announced in February 2025. U.S. demand for Foundayo is rising, with the drug generating $98 million in sales in its first full quarter. A new Medicare coverage for obesity drugs, effective July, is expected to further boost access to Foundayo and Lilly's weight-loss drug Zepbound.
Show 3 older updatesHide older updates
Narrowing Prescription Gap Between Eli Lilly's Foundayo and Novo's Wegovy Pill Bodes Well for Lilly Investors
This Motley Fool analysis, published on Yahoo Finance on September 17, 2026, examines the competitive dynamics in the weight-loss drug market, focusing on the new oral GLP-1 drugs. Eli Lilly (LLY) holds 60% of the U.S. injectable GLP-1 market, while Novo Nordisk (NVO) has 38%. Both companies launched oral weight-loss pills in 2026: Novo's Wegovy pill (semaglutide) and Lilly's Foundayo (orforglipron). While Novo's pill leads with 183,000 prescriptions versus Foundayo's 47,500, the analyst Adria Cimino highlights that the gap is progressively narrowing, similar to the pattern seen earlier in the injectable market where Lilly eventually overtook Novo. The article notes that Foundayo can be taken any time of day with or without food, offering greater convenience than the Wegovy pill. The author suggests this trend could lead to Lilly repeating its market dominance in the oral segment, which is excellent news for Lilly investors. The analysis includes a caution that switching patients from existing injectables may be more difficult for Foundayo since it uses a different active ingredient (orforglipron) than Lilly's injectables (tirzepatide).
Lilly's Foundayo Captures 30% of New Oral Weight-Loss Patients, Challenging Novo Nordisk
Eli Lilly's newly launched oral obesity drug, Foundayo, has captured more than 30% of new U.S. patients starting oral weight-loss medicines, according to a Reuters report cited by Yahoo Finance. This rapid market share gain challenges Novo Nordisk's Wegovy pill, which previously held roughly 90% of the oral market. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use. Foundayo, launched in April 2026, is priced at $149 per month for self-pay patients and as low as $25 for eligible commercially insured patients. The article notes that Foundayo's early momentum could extend Lilly's GLP-1 leadership, as it overcomes patient preference for oral over injectable medicines. However, risks include pricing pressure from competition and the need to translate early prescription gains into sustained revenue. Novo Nordisk is studying lower-dose versions of its pill to improve affordability and tolerability.
Lilly's Foundayo Captures 30% of New Oral Weight-Loss Patients, Challenging Novo
Eli Lilly's newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, according to a Reuters report cited by Yahoo Finance. This rapid market share gain challenges Novo Nordisk's Wegovy pill, which initially held roughly 90% of the oral market, signaling the oral GLP-1 market is becoming a two-player competition. Foundayo was launched in the U.S. in April 2026, starting at $149 per month for self-pay patients and as low as $25 for eligible commercially insured patients. Lilly's SEC filing shows Mounjaro and Zepbound represented 65% of its revenue in the first half of 2026. The article notes Foundayo's formulation can be taken without food or water restrictions, and clinical data showed a 27.3-pound weight reduction at the highest dose. Risks include that the 30% share represents only new oral patients, not the overall obesity market, and Novo is studying lower-dose versions of its pill. Pricing competition could also pressure market economics.